{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:45:44Z","timestamp":1777020344980,"version":"3.51.4"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      While antipsychotics primarily target dopamine D\n                      <jats:sub>2<\/jats:sub>\n                      receptor, the putative synaptic mechanisms underlying their therapeutic effects remain unclear. Postsynaptic density (PSD) at glutamatergic synapses represents a dynamic protein network involved in synaptic plasticity and neurotransmission, whose dysfunction has been implicated in the pathophysiology of schizophrenia and bipolar disorder. This study aims to explore, for the first time, with a quantitative meta-analytical approach, how antipsychotic treatments affect PSD molecules across various brain regions in preclinical settings, which may overcome the heterogeneity of human studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed and meta-analyzed peer-reviewed preclinical studies reporting quantitative effects of typical and atypical antipsychotics on PSD-related outcomes. Statistical analyses used random-effects models, with heterogeneity assessed via \u03c4\u00b2, I\u00b2, and Cochran\u2019s Q. Separate meta-analyses were conducted for PSD protein type, brain region, animal type, and treatment paradigms. Meta-regressions assessed the impact of cofounding variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 81 studies (n\u2009=\u20092542; rodents=2510; monkeys=26), resulting in 226 meta-analyses. Both typical and atypical antipsychotics modulated PSD molecules albeit with different degree due to the drug receptor profile, dose, specific protein detected, brain region, and administration regimen. Haloperidol, amisulpride, and aripiprazole significantly increased PSD protein expression in the striatum. Acute olanzapine increased PSD molecules levels in striatal regions, reducing Arc expression in frontal cortex (SMD [95%CIs]=-2.15 [-2.7;-1.61], p\u2009&lt;\u20090.0001); chronic treatment had opposite effects. Clozapine increased Homer1a levels in dorsal (1.13 [0.41;1.86],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and ventral striatum (1.48 [0.72;2.24],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001), and cingulate cortex (2.12 [1.12;3.12], p\u2009&lt;\u20090.0001), as well as increased NMDAR subunits levels in frontal cortex.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41380-025-03351-z","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:19:41Z","timestamp":1763533181000},"page":"1142-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular and topographic mapping of antipsychotic effects: a meta-analysis of postsynaptic density proteins in animal models with translational implications"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0422-3415","authenticated-orcid":false,"given":"Giuseppe","family":"De Simone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-1181","authenticated-orcid":false,"given":"Michele","family":"De Prisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5961-6032","authenticated-orcid":false,"given":"Vincenzo","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licia","family":"Vellucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-414X","authenticated-orcid":false,"given":"Mariateresa","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-7126","authenticated-orcid":false,"given":"Giovanna","family":"Fico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-5013","authenticated-orcid":false,"given":"Felice","family":"Iasevoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-5652","authenticated-orcid":false,"given":"Andrea","family":"de Bartolomeis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"3351_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"3351_CR2","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1038\/s41380-020-00946-6","volume":"26","author":"T Kishi","year":"2021","unstructured":"Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Mishima K, et al. Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry. 2021;26:4146\u201357.","journal-title":"Mol Psychiatry"},{"key":"3351_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S2215-0366(24)00006-3","volume":"11","author":"V Oliva","year":"2024","unstructured":"Oliva V, Possidente C, De Prisco M, Fico G, Anmella G, Hidalgo-Mazzei D, et al. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis. Lancet Psychiatry. 2024;11:210\u201320.","journal-title":"Lancet Psychiatry"},{"key":"3351_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;394:939\u201351.","journal-title":"The Lancet"},{"key":"3351_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","volume":"27","author":"T Kishi","year":"2022","unstructured":"Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Nomura I, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2022;27:1136\u201344.","journal-title":"Mol Psychiatry"},{"key":"3351_CR6","first-page":"Cd013304","volume":"12","author":"V M\u00fchlbauer","year":"2021","unstructured":"M\u00fchlbauer V, M\u00f6hler R, Dichter MN, Zuidema SU, K\u00f6pke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12:Cd013304.","journal-title":"Cochrane Database Syst Rev"},{"key":"3351_CR7","doi-asserted-by":"publisher","first-page":"CD014965","DOI":"10.1002\/14651858.CD014965","volume":"2022","author":"N Meza","year":"2022","unstructured":"Meza N, Rees R, Escobar Liquitay CM, Franco JVA, Sguassero Y, Williams K, et al. Atypical antipsychotics for autism spectrum disorder: a network meta\u2010analysis. Cochrane Database Syst Rev. 2022;2022:CD014965. https:\/\/doi.org\/10.1002\/14651858.CD014965.","journal-title":"Cochrane Database Syst Rev"},{"key":"3351_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41572-020-00223-4","volume":"6","author":"JE Wilson","year":"2020","unstructured":"Wilson JE, Mart MF, Cunningham C, Shehabi Y, Girard TD, MacLullich AMJ, et al. Delirium. Nat Rev Dis Primers. 2020;6:90.","journal-title":"Nat Rev Dis Primers"},{"key":"3351_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","volume":"302","author":"NA Nu\u00f1ez","year":"2022","unstructured":"Nu\u00f1ez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. J Affect Disord. 2022;302:385\u2013400.","journal-title":"J Affect Disord"},{"key":"3351_CR10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","volume":"27","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2017","unstructured":"H\u00e1lfd\u00e1narson \u00d3, Zo\u00ebga H, Aagaard L, Bernardo M, Brandt L, Fust\u00e9 AC, et al. International trends in antipsychotic use: A study in 16 countries, 2005-14. Eur Neuropsychopharmacol. 2017;27:1064\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3351_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403:160\u201370.","journal-title":"Lancet"},{"key":"3351_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.biopsych.2024.05.014","volume":"96","author":"OD Howes","year":"2024","unstructured":"Howes OD, Dawkins E, Lobo MC, Kaar SJ, Beck K. New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction. Biol Psychiatry. 2024;96:638\u201350.","journal-title":"Biol Psychiatry"},{"key":"3351_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.euroneuro.2025.05.006","volume":"97","author":"E Vieta","year":"2025","unstructured":"Vieta E, Oliva V. Thinner and wiser? Prospects of GLP-1 agonists in psychiatry. Eur Neuropsychopharmacol. 2025;97:3\u20134.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3351_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.12688\/f1000research.155356.1","volume":"13","author":"S Siafis","year":"2024","unstructured":"Siafis S, Nomura N, Schneider-Thoma J, Bighelli I, Bannach-Brown A, Ramage FJ, et al. Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis. F1000Res. 2024;13:1017.","journal-title":"F1000Res"},{"key":"3351_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1208\/s12248-010-9247-4","volume":"13","author":"R de Greef","year":"2011","unstructured":"de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 2011;13:121\u201330.","journal-title":"AAPS J"},{"key":"3351_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.neubiorev.2017.09.027","volume":"85","author":"D Amato","year":"2018","unstructured":"Amato D, Vernon AC, Papaleo F. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. Neuroscience & Biobehavioral Reviews. 2018;85:146\u201359.","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"3351_CR17","doi-asserted-by":"crossref","unstructured":"Saint-Georges Z, MacDonald J, Al-Khalili R, Hamati R, Solmi M, Keshavan MS. et al. Cholinergic system in schizophrenia: A systematic review and meta-analysis. Mol Psychiatry. 2025;30:3301\u201315 (2025).","DOI":"10.1038\/s41380-025-03023-y"},{"key":"3351_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44301-z","volume":"15","author":"N B\u00e9nac","year":"2024","unstructured":"B\u00e9nac N, Ezequiel Saraceno G, Butler C, Kuga N, Nishimura Y, Yokoi T, et al. Non-canonical interplay between glutamatergic NMDA and dopamine receptors shapes synaptogenesis. Nat Commun. 2024;15:27.","journal-title":"Nat Commun"},{"key":"3351_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41699-021-00205-4","volume":"5","author":"M Ma","year":"2021","unstructured":"Ma M, Ni Y, Chi Z, Meng W, Yu H, Gong J, et al. Multiplexed neurochemical transmission emulated using a dual-excitatory synaptic transistor. npj 2D Materials and Applications. 2021;5:23.","journal-title":"npj 2D Materials and Applications"},{"key":"3351_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrn2540","volume":"10","author":"W Feng","year":"2009","unstructured":"Feng W, Zhang M. Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density. Nat Rev Neurosci. 2009;10:87\u201399.","journal-title":"Nat Rev Neurosci"},{"key":"3351_CR21","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1523\/JNEUROSCI.4424-08.2009","volume":"29","author":"J Zhang","year":"2009","unstructured":"Zhang J, Xu TX, Hallett PJ, Watanabe M, Grant SG, Isacson O, et al. PSD-95 uncouples dopamine-glutamate interaction in the D1\/PSD-95\/NMDA receptor complex. J Neurosci. 2009;29:2948\u201360.","journal-title":"J Neurosci"},{"key":"3351_CR22","doi-asserted-by":"publisher","first-page":"21901","DOI":"10.1074\/jbc.M301905200","volume":"278","author":"Z Xia","year":"2003","unstructured":"Xia Z, Gray JA, Compton-Toth BA, Roth BL. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem. 2003;278:21901\u20138.","journal-title":"J Biol Chem"},{"key":"3351_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45971-w","volume":"9","author":"AA Coley","year":"2019","unstructured":"Coley AA, Gao W-J. PSD-95 deficiency disrupts PFC-associated function and behavior during neurodevelopment. Sci Rep. 2019;9:9486.","journal-title":"Sci Rep"},{"key":"3351_CR24","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2019.11.020","volume":"179","author":"Consortium C-DGotPG","year":"2019","unstructured":"Consortium C-DGotPG. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179:1469\u201382.e1411.","journal-title":"Cell"},{"key":"3351_CR25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/npp.2015.218","volume":"41","author":"N Akula","year":"2016","unstructured":"Akula N, Wendland JR, Choi KH, McMahon FJ. An integrative genomic study implicates the postsynaptic density in the pathogenesis of bipolar disorder. Neuropsychopharmacology. 2016;41:886\u201395.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41380-018-0332-x","volume":"25","author":"OB Smeland","year":"2020","unstructured":"Smeland OB, Bahrami S, Frei O, Shadrin A, O\u2019Connell K, Savage J, et al. Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. Mol Psychiatry. 2020;25:844\u201353.","journal-title":"Mol Psychiatry"},{"key":"3351_CR27","first-page":"374","volume":"46","author":"A Berdenis van Berlekom","year":"2020","unstructured":"Berdenis van Berlekom A, Muflihah CH, Snijders G, MacGillavry HD, Middeldorp J, Hol EM, et al. Synapse pathology in schizophrenia: a meta-analysis of postsynaptic elements in postmortem brain studies. Schizophr Bull. 2020;46:374\u201386.","journal-title":"Schizophr Bull"},{"key":"3351_CR28","doi-asserted-by":"publisher","first-page":"e1015","DOI":"10.1038\/tp.2016.282","volume":"7","author":"T Dahoun","year":"2017","unstructured":"Dahoun T, Trossbach SV, Brandon NJ, Korth C, Howes OD. The impact of disrupted-in-schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. Transl Psychiatry. 2017;7:e1015.","journal-title":"Transl Psychiatry"},{"key":"3351_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pnpbp.2017.10.011","volume":"81","author":"F Benedetti","year":"2018","unstructured":"Benedetti F, Poletti S, Locatelli C, Mazza E, Lorenzi C, Vitali A, et al. A homer 1 gene variant influences brain structure and function, lithium effects on white matter, and antidepressant response in bipolar disorder: A multimodal genetic imaging study. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:88\u201395.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3351_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14122-0","volume":"11","author":"EC Onwordi","year":"2020","unstructured":"Onwordi EC, Halff EF, Whitehurst T, Mansur A, Cotel M-C, Wells L, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun. 2020;11:246.","journal-title":"Nat Commun"},{"key":"3351_CR31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","volume":"70","author":"RS Kahn","year":"2013","unstructured":"Kahn RS, Keefe RSE. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry. 2013;70:1107\u201312.","journal-title":"JAMA Psychiatry"},{"key":"3351_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.euroneuro.2008.07.005","volume":"18","author":"GM Goodwin","year":"2008","unstructured":"Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol. 2008;18:787\u201393.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3351_CR33","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28:1902\u201318.","journal-title":"Mol Psychiatry"},{"key":"3351_CR34","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41380-023-02043-w","volume":"28","author":"OD Howes","year":"2023","unstructured":"Howes OD, Onwordi EC. The synaptic hypothesis of schizophrenia version III: a master mechanism. Mol Psychiatry. 2023;28:1843\u201356.","journal-title":"Mol Psychiatry"},{"key":"3351_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101135","volume":"48","author":"V Oliva","year":"2025","unstructured":"Oliva V, Fico G, De Prisco M, Gonda X, Rosa AR, Vieta E. Bipolar disorders: an update on critical aspects. Lancet Reg Health Eur. 2025;48:101135.","journal-title":"Lancet Reg Health Eur"},{"key":"3351_CR36","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0006-3223(01)01267-7","volume":"50","author":"C Konradi","year":"2001","unstructured":"Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry. 2001;50:729\u201342.","journal-title":"Biol Psychiatry"},{"key":"3351_CR37","doi-asserted-by":"publisher","first-page":"e1146","DOI":"10.1038\/tp.2017.120","volume":"7","author":"M Morais","year":"2017","unstructured":"Morais M, Patr\u00edcio P, Mateus-Pinheiro A, Alves ND, Machado-Santos AR, Correia JS, et al. The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression. Transl Psychiatry. 2017;7:e1146.","journal-title":"Transl Psychiatry"},{"key":"3351_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41537-024-00476-y","volume":"10","author":"O L\u00e1nyi","year":"2024","unstructured":"L\u00e1nyi O, Kolesz\u00e1r B, Schulze Wenning A, Balogh D, Engh MA, Horv\u00e1th AA, et al. Excitation\/inhibition imbalance in schizophrenia: a meta-analysis of inhibitory and excitatory TMS-EMG paradigms. Schizophrenia. 2024;10:56.","journal-title":"Schizophrenia"},{"key":"3351_CR39","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.3390\/ijms24054372","volume":"24","author":"A Barone","year":"2023","unstructured":"Barone A, De Simone G, Ciccarelli M, Buonaguro EF, Tomasetti C, Eramo A, et al. A postsynaptic density immediate early gene-based connectome analysis of acute NMDAR blockade and reversal effect of antipsychotic administration. Int J Mol Sci. 2023;24:4372.","journal-title":"Int J Mol Sci"},{"key":"3351_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/0269881116658987","volume":"31","author":"EF Buonaguro","year":"2017","unstructured":"Buonaguro EF, Tomasetti C, Chiodini P, Marmo F, Latte G, Rossi R, et al. Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. J Psychopharmacol. 2017;31:406\u201317.","journal-title":"J Psychopharmacol"},{"key":"3351_CR41","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.pnpbp.2009.02.009","volume":"33","author":"F Iasevoli","year":"2009","unstructured":"Iasevoli F, Tomasetti C, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Dopamine receptor subtypes contribution to homer1a induction: insights into antipsychotic molecular action. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009;33:813\u201321.","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"3351_CR42","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00001756-200002280-00025","volume":"11","author":"T Nakahara","year":"2000","unstructured":"Nakahara T, Kuroki T, Hashimoto K, Hondo H, Tsutsumi T, Motomura K, et al. Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain. Neuroreport. 2000;11:551\u20135.","journal-title":"Neuroreport"},{"key":"3351_CR43","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1124\/mol.107.043786","volume":"73","author":"F Fumagalli","year":"2008","unstructured":"Fumagalli F, Frasca A, Racagni G, Riva MA. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol. 2008;73:1484\u201390.","journal-title":"Mol Pharmacol"},{"key":"3351_CR44","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/s41380-024-02503-x","volume":"29","author":"K Allott","year":"2024","unstructured":"Allott K, Chopra S, Rogers J, Dauvermann MR, Clark SR. Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action. Mol Psychiatry. 2024;29:2571\u20134.","journal-title":"Mol Psychiatry"},{"key":"3351_CR45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41537-024-00535-4","volume":"10","author":"G De Simone","year":"2024","unstructured":"De Simone G, Iasevoli F, Barone A, Gaudieri V, Cuocolo A, Ciccarelli M, et al. Addressing brain metabolic connectivity in treatment-resistant schizophrenia: a novel graph theory-driven application of 18F-FDG-PET with antipsychotic dose correction. Schizophrenia. 2024;10:116.","journal-title":"Schizophrenia"},{"key":"3351_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.biopsych.2024.01.010","volume":"96","author":"JO Maximo","year":"2024","unstructured":"Maximo JO, Armstrong WP, Kraguljac NV, Lahti AC. Higher-order intrinsic brain network trajectories after antipsychotic treatment in medication-Na\u00efve patients with first-episode psychosis. Biol Psychiatry. 2024;96:198\u2013206.","journal-title":"Biol Psychiatry"},{"key":"3351_CR47","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1038\/s41380-023-02118-8","volume":"28","author":"NH Neufeld","year":"2023","unstructured":"Neufeld NH, Oliver LD, Mulsant BH, Alexopoulos GS, Hoptman MJ, Tani H, et al. Effects of antipsychotic medication on functional connectivity in major depressive disorder with psychotic features. Mol Psychiatry. 2023;28:3305\u201313.","journal-title":"Mol Psychiatry"},{"key":"3351_CR48","doi-asserted-by":"publisher","first-page":"pyae018","DOI":"10.1093\/ijnp\/pyae018","volume":"27","author":"M Direktor","year":"2024","unstructured":"Direktor M, Gass P, Inta D. Understanding the therapeutic action of antipsychotics: from molecular to cellular targets with focus on the islands of calleja. Int J Neuropsychopharmacol. 2024;27:pyae018.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3351_CR49","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3351_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bbr.2007.12.029","volume":"189","author":"SL McLean","year":"2008","unstructured":"McLean SL, Beck JP, Woolley ML, Neill JC. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res. 2008;189:152\u20138.","journal-title":"Behav Brain Res"},{"key":"3351_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s002130100818","volume":"156","author":"MP Andersen","year":"2001","unstructured":"Andersen MP, Pouzet B. Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology (Berl). 2001;156:291\u2013304.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.","journal-title":"BMC Med Res Methodol"},{"key":"3351_CR53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/01621459.1977.10480998","volume":"72","author":"DA Harville","year":"1977","unstructured":"Harville DA. Maximum likelihood approaches to variance component estimation and to related problems. J Am Stat Assoc. 1977;72:320\u201338.","journal-title":"J Am Stat Assoc"},{"key":"3351_CR54","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"3351_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/biomet\/37.3-4.256","volume":"37","author":"WG Cochran","year":"1950","unstructured":"Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256\u201366.","journal-title":"Biometrika"},{"key":"3351_CR56","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"3351_CR57","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41380-024-02719-x","volume":"30","author":"MM Friske","year":"2025","unstructured":"Friske MM, Torrico EC, Haas MJW, Borruto AM, Giannone F, Hade A-C, et al. A systematic review and meta-analysis on the transcriptomic signatures in alcohol use disorder. Mol Psychiatry. 2025;30:310\u201326.","journal-title":"Mol Psychiatry"},{"key":"3351_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01352-4","volume":"11","author":"M Rocha","year":"2021","unstructured":"Rocha M, Wang D, Avila-Quintero V, Bloch MH, Kaffman A. Deficits in hippocampal-dependent memory across different rodent models of early life stress: systematic review and meta-analysis. Transl Psychiatry. 2021;11:231.","journal-title":"Transl Psychiatry"},{"key":"3351_CR59","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1038\/s41380-023-02065-4","volume":"28","author":"A de Bartolomeis","year":"2023","unstructured":"de Bartolomeis A, De Simone G, De Prisco M, Barone A, Napoli R, Beguinot F, et al. Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment. Mol Psychiatry. 2023;28:2811\u201325.","journal-title":"Mol Psychiatry"},{"key":"3351_CR60","volume-title":"Integrated Development for R","author":"RStudio","year":"2020","unstructured":"RStudio. Integrated Development for R. Boston, MA: RStudio P; 2020. http:\/\/www.rstudio.com\/."},{"key":"3351_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"3351_CR62","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"ML Waskom","year":"2021","unstructured":"Waskom ML. seaborn: statistical data visualization. Journal of Open Source Software. 2021;6:3021 https:\/\/doi.org\/10.21105\/joss.03021.","journal-title":"Journal of Open Source Software"},{"key":"3351_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1109\/MCSE.2011.35","volume":"13","author":"P Ramachandran","year":"2011","unstructured":"Ramachandran P, Varoquaux G. Mayavi: 3D visualization of scientific data. Computing in Science and Engg. 2011;13:40\u201351.","journal-title":"Computing in Science and Engg"},{"key":"3351_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13575-7","volume":"10","author":"DA Barri\u00e8re","year":"2019","unstructured":"Barri\u00e8re DA, Magalh\u00e3es R, Novais A, Marques P, Selingue E, Geffroy F, et al. The SIGMA rat brain templates and atlases for multimodal MRI data analysis and visualization. Nat Commun. 2019;10:5699.","journal-title":"Nat Commun"},{"key":"3351_CR65","doi-asserted-by":"publisher","first-page":"12203","DOI":"10.3390\/ijms222212203","volume":"22","author":"A Korlatowicz","year":"2021","unstructured":"Korlatowicz A, Ku\u015bmider M, Szlachta M, Pabian P, Solich J, Dziedzicka-Wasylewska M, et al. Identification of molecular markers of clozapine action in ketamine-induced cognitive impairment: A GPCR signaling pathwayfinder study. Int J Mol Sci. 2021;22:12203.","journal-title":"Int J Mol Sci"},{"key":"3351_CR66","first-page":"22","volume":"13","author":"GS Mahmoud","year":"2021","unstructured":"Mahmoud GS, Hosny G, Sayed SA. The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia. Int J Physiol Pathophysiol Pharmacol. 2021;13:22\u201335.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"3351_CR67","first-page":"pyu041","volume":"18","author":"FV Gomes","year":"2014","unstructured":"Gomes FV, Issy AC, Ferreira FR, Viveros MP, Del Bel EA, Guimar\u00e3es FS. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol. 2014;18:pyu041.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3351_CR68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.31083\/j.jin2106164","volume":"21","author":"X Liu","year":"2022","unstructured":"Liu X, Feng S, Feng Z, Ma C, He Y, Li X, et al. Protective effects of shi-zhen-an-shen decoction on the cognitive impairment in MK801-induced schizophrenia model. J Integr Neurosci. 2022;21:164.","journal-title":"J Integr Neurosci"},{"key":"3351_CR69","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.schres.2014.07.054","volume":"159","author":"C Zhang","year":"2014","unstructured":"Zhang C, Fang Y, Xu L. Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. Schizophr Res. 2014;159:376\u201384.","journal-title":"Schizophr Res"},{"key":"3351_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02509-z","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou X, Cai G, Mao S, Xu D, Xu X, Zhang R, et al. Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action. BMC Psychiatry. 2020;20:106.","journal-title":"BMC Psychiatry"},{"key":"3351_CR71","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00213-023-06434-3","volume":"240","author":"AC Dutra-Tavares","year":"2023","unstructured":"Dutra-Tavares AC, Souza TP, Silva JO, Seme\u00e3o KA, Mello FF, Filgueiras CC, et al. Neonatal phencyclidine as a model of sex-biased schizophrenia symptomatology in adolescent mice. Psychopharmacology (Berl). 2023;240:2111\u201329.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR72","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/npp.2014.207","volume":"40","author":"H Hida","year":"2015","unstructured":"Hida H, Mouri A, Mori K, Matsumoto Y, Seki T, Taniguchi M, et al. Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D\u2083-5-HT\u2082A and D\u2081-NMDA receptors in the mPFC. Neuropsychopharmacology. 2015;40:601\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR73","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/FPC.0b013e32832ee573","volume":"19","author":"M Orsetti","year":"2009","unstructured":"Orsetti M, Di Brisco F, Rinaldi M, Dallorto D, Ghi P. Some molecular effectors of antidepressant action of quetiapine revealed by DNA microarray in the frontal cortex of anhedonic rats. Pharmacogenet Genomics. 2009;19:600\u201312.","journal-title":"Pharmacogenet Genomics"},{"key":"3351_CR74","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.psychres.2015.05.098","volume":"229","author":"MK Seo","year":"2015","unstructured":"Seo MK, Lee CH, Cho HY, You YS, Lee BJ, Lee JG, et al. Effects of antipsychotic drugs on the expression of synapse-associated proteins in the frontal cortex of rats subjected to immobilization stress. Psychiatry Res. 2015;229:968\u201374.","journal-title":"Psychiatry Res"},{"key":"3351_CR75","doi-asserted-by":"publisher","first-page":"137886","DOI":"10.1016\/j.neulet.2024.137886","volume":"836","author":"T Buck","year":"2024","unstructured":"Buck T, Dong E, McCarthy M, Guidotti A, Sodhi M. Prenatal stress alters transcription of NMDA-type glutamate receptors in the hippocampus. Neurosci Lett. 2024;836:137886.","journal-title":"Neurosci Lett"},{"key":"3351_CR76","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1471-4159.2005.03558.x","volume":"96","author":"K H\u00e5kansson","year":"2006","unstructured":"H\u00e5kansson K, Galdi S, Hendrick J, Snyder G, Greengard P, Fisone G. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem. 2006;96:482\u20138.","journal-title":"J Neurochem"},{"key":"3351_CR77","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1007\/s00213-017-4704-8","volume":"234","author":"Y Matsumoto","year":"2017","unstructured":"Matsumoto Y, Niwa M, Mouri A, Noda Y, Fukushima T, Ozaki N, et al. Adolescent stress leads to glutamatergic disturbance through dopaminergic abnormalities in the prefrontal cortex of genetically vulnerable mice. Psychopharmacology (Berl). 2017;234:3055\u201374.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-3223(00)01058-1","volume":"49","author":"MS Lidow","year":"2001","unstructured":"Lidow MS, Song ZM, Castner SA, Allen PB, Greengard P, Goldman-Rakic PS. Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol Psychiatry. 2001;49:1\u201312.","journal-title":"Biol Psychiatry"},{"key":"3351_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0116-8","volume":"8","author":"AC Kao","year":"2018","unstructured":"Kao AC, Spitzer S, Anthony DC, Lennox B, Burnet PWJ. Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. Transl Psychiatry. 2018;8:66.","journal-title":"Transl Psychiatry"},{"key":"3351_CR80","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S0169-328X(97)00326-4","volume":"54","author":"AC Chen","year":"1998","unstructured":"Chen AC, McDonald B, Moss SJ, Gurling HM. Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis-and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment. Brain Res Mol Brain Res. 1998;54:92\u2013100.","journal-title":"Brain Res Mol Brain Res"},{"key":"3351_CR81","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/syn.20385","volume":"61","author":"A Ambesi-Impiombato","year":"2007","unstructured":"Ambesi-Impiombato A, Panariello F, Dell\u2019aversano C, Tomasetti C, Muscettola G, de Bartolomeis A. Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse. 2007;61:429\u201339.","journal-title":"Synapse"},{"key":"3351_CR82","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.euroneuro.2008.09.001","volume":"19","author":"F Fumagalli","year":"2009","unstructured":"Fumagalli F, Frasca A, Racagni G, Riva MA. Antipsychotic drugs modulate Arc expression in the rat brain. Eur Neuropsychopharmacol. 2009;19:109\u201315.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3351_CR83","doi-asserted-by":"publisher","first-page":"e0118510","DOI":"10.1371\/journal.pone.0118510","volume":"10","author":"K Sakuma","year":"2015","unstructured":"Sakuma K, Komatsu H, Maruyama M, Imaichi S, Habata Y, Mori M. Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain. PLoS One. 2015;10:e0118510.","journal-title":"PLoS One"},{"key":"3351_CR84","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1523\/JNEUROSCI.22-23-10067.2002","volume":"22","author":"A Vazdarjanova","year":"2002","unstructured":"Vazdarjanova A, McNaughton BL, Barnes CA, Worley PF, Guzowski JF. Experience-dependent coincident expression of the effector immediate-early genes arc and Homer 1a in hippocampal and neocortical neuronal networks. J Neurosci. 2002;22:10067\u201371.","journal-title":"J Neurosci"},{"key":"3351_CR85","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0169-328X(97)00175-7","volume":"50","author":"MA Riva","year":"1997","unstructured":"Riva MA, Tascedda F, Lovati E, Racagni G. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res. 1997;50:136\u201342.","journal-title":"Brain Res Mol Brain Res"},{"key":"3351_CR86","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0306-4522(97)00490-9","volume":"84","author":"S Bren\u00e9","year":"1998","unstructured":"Bren\u00e9 S, Messer C, Nestler EJ. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: regulation by haloperidol. Neuroscience. 1998;84:813\u201323.","journal-title":"Neuroscience"},{"key":"3351_CR87","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/026988119400800402","volume":"8","author":"SL Eastwood","year":"1994","unstructured":"Eastwood SL, Story P, Burnet PW, Heath P, Harrison PJ. Differential changes in glutamate receptor subunit messenger RNAs in rat brain after haloperidol treatment. J Psychopharmacol. 1994;8:196\u2013203.","journal-title":"J Psychopharmacol"},{"key":"3351_CR88","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00213-010-1954-0","volume":"212","author":"F Iasevoli","year":"2010","unstructured":"Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, de Bartolomeis A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology (Berl). 2010;212:329\u201344.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR89","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1523\/JNEUROSCI.15-03-02453.1995","volume":"15","author":"LW Fitzgerald","year":"1995","unstructured":"Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci. 1995;15:2453\u201361.","journal-title":"J Neurosci"},{"key":"3351_CR90","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1023\/A:1023231611616","volume":"28","author":"T Hanaoka","year":"2003","unstructured":"Hanaoka T, Toyoda H, Mizuno T, Kikuyama H, Morimoto K, Takahata R, et al. Alterations in NMDA receptor subunit levels in the brain regions of rats chronically administered typical or atypical antipsychotic drugs. Neurochem Res. 2003;28:919\u201324.","journal-title":"Neurochem Res"},{"key":"3351_CR91","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0896-6273(04)00072-8","volume":"41","author":"Z Cui","year":"2004","unstructured":"Cui Z, Wang H, Tan Y, Zaia KA, Zhang S, Tsien JZ. Inducible and reversible NR1 knockout reveals crucial role of the NMDA receptor in preserving remote memories in the brain. Neuron. 2004;41:781\u201393.","journal-title":"Neuron"},{"key":"3351_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113160","volume":"404","author":"A Barone","year":"2021","unstructured":"Barone A, Signoriello S, Latte G, Vellucci L, Giordano G, Avagliano C, et al. Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: translational inference from a postsynaptic density immediate-early gene-based network analysis. Behav Brain Res. 2021;404:113160.","journal-title":"Behav Brain Res"},{"key":"3351_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pnpbp.2017.02.012","volume":"76","author":"EF Buonaguro","year":"2017","unstructured":"Buonaguro EF, Iasevoli F, Marmo F, Eramo A, Latte G, Avagliano C, et al. Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling. Prog Neuropsychopharmacol Biol Psychiatry. 2017;76:29\u201341.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3351_CR94","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.euroneuro.2015.01.003","volume":"25","author":"A de Bartolomeis","year":"2015","unstructured":"de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Eramo A, Rossi R, et al. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. Eur Neuropsychopharmacol. 2015;25:566\u201382.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3351_CR95","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.brainresbull.2009.01.006","volume":"79","author":"C Dell\u2019aversano","year":"2009","unstructured":"Dell\u2019aversano C, Tomasetti C, Iasevoli F, de Bartolomeis A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Res Bull. 2009;79:123\u20139.","journal-title":"Brain Res Bull"},{"key":"3351_CR96","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.pnpbp.2010.10.025","volume":"35","author":"C Tomasetti","year":"2011","unstructured":"Tomasetti C, Dell\u2019Aversano C, Iasevoli F, Marmo F, de Bartolomeis A. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:184\u201397.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3351_CR97","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.neuroscience.2007.08.022","volume":"150","author":"C Tomasetti","year":"2007","unstructured":"Tomasetti C, Dell\u2019Aversano C, Iasevoli F, de Bartolomeis A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience. 2007;150:144\u201358.","journal-title":"Neuroscience"},{"key":"3351_CR98","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/0269881109358199","volume":"25","author":"F Iasevoli","year":"2011","unstructured":"Iasevoli F, Ambesi-Impiombato A, Fiore G, Panariello F, Muscettola G, de Bartolomeis A. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. J Psychopharmacol. 2011;25:875\u201387.","journal-title":"J Psychopharmacol"},{"key":"3351_CR99","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pnpbp.2016.04.015","volume":"70","author":"A de Bartolomeis","year":"2016","unstructured":"de Bartolomeis A, Marmo F, Buonaguro EF, Latte G, Tomasetti C, Iasevoli F. Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-na\u00efve vs. antipsychotic-exposed rats. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:24\u201338.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3351_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2020.100013","volume":"2","author":"DW Yakout","year":"2021","unstructured":"Yakout DW, Shree N, Mabb AM. Effect of pharmacological manipulations on Arc function. Current Research in Pharmacology and Drug Discovery. 2021;2:100013.","journal-title":"Current Research in Pharmacology and Drug Discovery"},{"key":"3351_CR101","first-page":"3600","volume":"27","author":"Y Ye","year":"2017","unstructured":"Ye Y, Mastwal S, Cao VY, Ren M, Liu Q, Zhang W, et al. Dopamine is required for activity-dependent amplification of Arc mRNA in developing postnatal frontal cortex. Cereb Cortex. 2017;27:3600\u20138.","journal-title":"Cereb Cortex"},{"key":"3351_CR102","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s002130050877","volume":"142","author":"I Ninan","year":"1999","unstructured":"Ninan I, Kulkarni SK. Differential effects of olanzapine at dopamine D1 and D2 receptors in dopamine depleted animals. Psychopharmacology (Berl). 1999;142:175\u201381.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR103","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.celrep.2016.07.044","volume":"16","author":"F Manag\u00f2","year":"2016","unstructured":"Manag\u00f2 F, Mereu M, Mastwal S, Mastrogiacomo R, Scheggia D, Emanuele M, et al. Genetic disruption of Arc\/Arg3.1 in mice causes alterations in dopamine and neurobehavioral phenotypes related to schizophrenia. Cell Reports. 2016;16:2116\u201328.","journal-title":"Cell Reports"},{"key":"3351_CR104","first-page":"147","volume":"5","author":"NE Clifton","year":"2019","unstructured":"Clifton NE, Trent S, Thomas KL, Hall J. Regulation and function of activity-dependent homer in synaptic plasticity. Mol Neuropsychiatry. 2019;5:147\u201361.","journal-title":"Mol Neuropsychiatry"},{"key":"3351_CR105","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.conb.2006.05.002","volume":"16","author":"KK Szumlinski","year":"2006","unstructured":"Szumlinski KK, Kalivas PW, Worley PF. Homer proteins: implications for neuropsychiatric disorders. Curr Opin Neurobiol. 2006;16:251\u20137.","journal-title":"Curr Opin Neurobiol"},{"key":"3351_CR106","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.schres.2016.07.019","volume":"176","author":"Y-A Chuang","year":"2016","unstructured":"Chuang Y-A, Hu T-M, Chen C-H, Hsu S-H, Tsai H-Y, Cheng M-C. Rare mutations and hypermethylation of the ARC gene associated with schizophrenia. Schizophr Res. 2016;176:106\u201313.","journal-title":"Schizophr Res"},{"key":"3351_CR107","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jpsychires.2010.06.004","volume":"45","author":"I Spellmann","year":"2011","unstructured":"Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, et al. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J Psychiatr Res. 2011;45:234\u201341.","journal-title":"J Psychiatr Res"},{"key":"3351_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/npjschz.2015.37","volume":"1","author":"VS Catts","year":"2015","unstructured":"Catts VS, Derminio DS, Hahn C-G, Weickert CS. Postsynaptic density levels of the NMDA receptor NR1 subunit and PSD-95 protein in prefrontal cortex from people with schizophrenia. NPJ Schizophr. 2015;1:15037.","journal-title":"NPJ Schizophr"},{"key":"3351_CR109","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/mp.2012.137","volume":"18","author":"CS Weickert","year":"2013","unstructured":"Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM, Moore LT, et al. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry. 2013;18:1185\u201392.","journal-title":"Mol Psychiatry"},{"key":"3351_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-025-06950-w","volume":"25","author":"Z Mao","year":"2025","unstructured":"Mao Z, Li F, Ge L, Hou W, Ding Y, Wang F, et al. Serum NR1 and NR2 concentrations in first-episode schizophrenia and clinical high-risk for psychosis. BMC Psychiatry. 2025;25:493.","journal-title":"BMC Psychiatry"},{"key":"3351_CR111","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.brainres.2006.09.011","volume":"1127","author":"RE McCullumsmith","year":"2007","unstructured":"McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 2007;1127:108\u201318.","journal-title":"Brain Res"},{"key":"3351_CR112","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41386-024-01943-x","volume":"50","author":"O Howes","year":"2025","unstructured":"Howes O, Marcinkowska J, Turkheimer FE, Carr R. Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging. Neuropsychopharmacology. 2025;50:164\u201383.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02479-2","volume":"13","author":"S Jauhar","year":"2023","unstructured":"Jauhar S, McCutcheon RA, Veronese M, Borgan F, Nour M, Rogdaki M, et al. The relationship between striatal dopamine and anterior cingulate glutamate in first episode psychosis changes with antipsychotic treatment. Transl Psychiatry. 2023;13:184.","journal-title":"Transl Psychiatry"},{"key":"3351_CR114","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2045125318781475","volume":"8","author":"PM Haddad","year":"2018","unstructured":"Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8:303\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"key":"3351_CR115","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/wps.20521","volume":"17","author":"R Emsley","year":"2018","unstructured":"Emsley R. Antipsychotic maintenance treatment in schizophrenia and the importance of preventing relapse. World Psychiatry. 2018;17:168\u20139.","journal-title":"World Psychiatry"},{"key":"3351_CR116","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17:149\u201360.","journal-title":"World Psychiatry"},{"key":"3351_CR117","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/npp.2011.296","volume":"37","author":"R Coccurello","year":"2012","unstructured":"Coccurello R, Oliverio A, Mele A. Dopamine\u2013glutamate interplay in the ventral striatum modulates spatial learning in a receptor subtype-dependent manner. Neuropsychopharmacology. 2012;37:1122\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR118","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0149-7634(96)00029-2","volume":"21","author":"P Calabresi","year":"1997","unstructured":"Calabresi P, Pisani A, Centonze D, Bernardi G. Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci Biobehav Rev. 1997;21:519\u201323.","journal-title":"Neurosci Biobehav Rev"},{"key":"3351_CR119","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","volume":"94","author":"A Breier","year":"1997","unstructured":"Breier A, Su T-P, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography\u2009method. Proceedings of the National Academy of Sciences. 1997;94:2569\u201374.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"3351_CR120","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/syn.20734","volume":"64","author":"M Slifstein","year":"2010","unstructured":"Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, et al. Striatal and extrastriatal dopamine release measured with PET and [18F] fallypride. Synapse. 2010;64:350\u201362.","journal-title":"Synapse"},{"key":"3351_CR121","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/026988119901300405","volume":"13","author":"M Laruelle","year":"1999","unstructured":"Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999;13:358\u201371.","journal-title":"J Psychopharmacol"},{"key":"3351_CR122","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.biopsych.2017.11.032","volume":"83","author":"WG Frankle","year":"2018","unstructured":"Frankle WG, Paris J, Himes M, Mason NS, Mathis CA, Narendran R. Amphetamine-induced striatal dopamine release measured with an agonist radiotracer in schizophrenia. Biol Psychiatry. 2018;83:707\u201314.","journal-title":"Biol Psychiatry"},{"key":"3351_CR123","first-page":"1040","volume":"5","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Jauhar S, Pepper F, Nour MM, Rogdaki M, Veronese M, et al. The topography of striatal dopamine and symptoms in psychosis: an integrative positron emission tomography and magnetic resonance imaging study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:1040\u201351.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"3351_CR124","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/mp.2011.20","volume":"16","author":"O Howes","year":"2011","unstructured":"Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry. 2011;16:885\u20136.","journal-title":"Mol Psychiatry"},{"key":"3351_CR125","doi-asserted-by":"publisher","first-page":"s13","DOI":"10.1192\/bjp.191.51.s13","volume":"191","author":"OD Howes","year":"2007","unstructured":"Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. British Journal of Psychiatry. 2007;191:s13\u20138.","journal-title":"British Journal of Psychiatry"},{"key":"3351_CR126","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/S1053-8119(09)71338-2","volume":"47","author":"TB Koontz","year":"2009","unstructured":"Koontz TB, Bolding M, White D, Lahti AC. Haloperidol increases striatal rCBF and alters functional connectivity in cortico-striatal neural networks. Neuroimage. 2009;47:S136.","journal-title":"Neuroimage"},{"key":"3351_CR127","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00213-002-1082-6","volume":"162","author":"J Tauscher","year":"2002","unstructured":"Tauscher J, K\u00fcfferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl). 2002;162:42\u201349.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR128","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0006-3223(02)01602-5","volume":"53","author":"AC Lahti","year":"2003","unstructured":"Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Tamminga CA. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry. 2003;53:601\u20138.","journal-title":"Biol Psychiatry"},{"key":"3351_CR129","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fnins.2020.00484","volume":"14","author":"HG Andersen","year":"2020","unstructured":"Andersen HG, Raghava JM, Svarer C, Wulff S, Johansen LB, Antonsen PK, et al. Striatal volume increase after six weeks of selective dopamine D(2\/3) receptor blockade in first-episode, antipsychotic-na\u00efve schizophrenia patients. Front Neurosci. 2020;14:484.","journal-title":"Front Neurosci"},{"key":"3351_CR130","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jpsychires.2024.01.020","volume":"171","author":"S Feng","year":"2024","unstructured":"Feng S, Zheng S, Dong L, Li Z, Zhu H, Liu S, et al. Effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-na\u00efve schizophrenia patients. J Psychiatr Res. 2024;171:215\u201321.","journal-title":"J Psychiatr Res"},{"key":"3351_CR131","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.biopsych.2011.12.004","volume":"71","author":"AC Vernon","year":"2012","unstructured":"Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SC, et al. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry. 2012;71:855\u201363.","journal-title":"Biol Psychiatry"},{"key":"3351_CR132","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.pnpbp.2008.09.020","volume":"32","author":"B Crespo-Facorro","year":"2008","unstructured":"Crespo-Facorro B, Roiz-Santi\u00e1\u00f1ez R, P\u00e9rez-Iglesias R, Pelayo-Ter\u00e1n JM, Rodr\u00edguez-S\u00e1nchez JM, Tordesillas-Guti\u00e9rrez D, et al. Effect of antipsychotic drugs on brain morphometry.: A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008;32:1936\u201343.","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"3351_CR133","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/hbm.23844","volume":"39","author":"PCT Hawkins","year":"2018","unstructured":"Hawkins PCT, Wood TC, Vernon AC, Bertolino A, Sambataro F, Dukart J, et al. An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers. Hum Brain Mapp. 2018;39:319\u201331.","journal-title":"Hum Brain Mapp"},{"key":"3351_CR134","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2009.08.019","volume":"620","author":"LA Bruins Slot","year":"2009","unstructured":"Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D. F15063, a potential antipsychotic with dopamine D(2)\/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur J Pharmacol. 2009;620:27\u201335.","journal-title":"Eur J Pharmacol"},{"key":"3351_CR135","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00702-014-1231-1","volume":"121","author":"S Waters","year":"2014","unstructured":"Waters S, Ponten H, Edling M, Svanberg B, Klamer D, Waters N. The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm (Vienna). 2014;121:1337\u201347.","journal-title":"J Neural Transm (Vienna)"},{"key":"3351_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/srep30040","volume":"6","author":"B Pan","year":"2016","unstructured":"Pan B, Huang XF, Deng C. Chronic administration of aripiprazole activates GSK3\u03b2-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats. Sci Rep. 2016;6:30040.","journal-title":"Sci Rep"},{"key":"3351_CR137","doi-asserted-by":"publisher","unstructured":"Guarnieri RV, Alves MV, Nogueira AML, de Souza Silva Tudesco I, Galdur\u00f3z JCF, Covolan L, et al. Haloperidol-induced impairment on working memory capacity affecting long term memory performance: the binding hypothesis. bioRxiv 2019. 2019.2012.2024.888073. https:\/\/doi.org\/10.1101\/2019.12.24.888073.","DOI":"10.1101\/2019.12.24.888073"},{"key":"3351_CR138","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.biopsych.2006.03.044","volume":"60","author":"JA O\u2019Connor","year":"2006","unstructured":"O\u2019Connor JA, Hasenkamp W, Horman BM, Muly EC, Hemby SE. Region specific regulation of NR1 in rhesus monkeys following chronic antipsychotic drug administration. Biol Psychiatry. 2006;60:659\u201362.","journal-title":"Biol Psychiatry"},{"key":"3351_CR139","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pscychresns.2008.09.001","volume":"173","author":"G Blasi","year":"2009","unstructured":"Blasi G, Popolizio T, Taurisano P, Caforio G, Romano R, Di Giorgio A, et al. Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia. Psychiatry Res. 2009;173:31\u201338.","journal-title":"Psychiatry Res"},{"key":"3351_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2023.102316","volume":"132","author":"GD Flores-G\u00f3mez","year":"2023","unstructured":"Flores-G\u00f3mez GD, Apam-Castillejos DJ, Ju\u00e1rez-D\u00edaz I, Fuentes-Medel E, D\u00edaz A, Tendilla-Beltr\u00e1n H, et al. Aripiprazole attenuates the medial prefrontal cortex morphological and biochemical alterations in rats with neonatal ventral hippocampus lesion. J Chem Neuroanat. 2023;132:102316.","journal-title":"J Chem Neuroanat"},{"key":"3351_CR141","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00213-016-4234-9","volume":"233","author":"A Murphy","year":"2016","unstructured":"Murphy A, Dursun S, McKie S, Elliott R, Deakin JF. An investigation into aripiprazole\u2019s partial D\u2082 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Psychopharmacology (Berl). 2016;233:1415\u201326.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR142","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41380-018-0042-4","volume":"24","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Turkheimer FE, et al. Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Mol Psychiatry. 2019;24:1502\u201312.","journal-title":"Mol Psychiatry"},{"key":"3351_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56663-7","volume":"16","author":"M Osugo","year":"2025","unstructured":"Osugo M, Wall MB, Selvaggi P, Zahid U, Finelli V, Chapman GE, et al. Striatal dopamine D2\/D3 receptor regulation of human reward processing and behaviour. Nat Commun. 2025;16:1852.","journal-title":"Nat Commun"},{"key":"3351_CR144","doi-asserted-by":"crossref","unstructured":"Chen C, Masotti M, Shepard N, Promes V, Tombesi G, Arango D, et al. LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons. Mol Psychiatry. 2025;30:4473\u201386.","DOI":"10.1038\/s41380-025-03030-z"},{"key":"3351_CR145","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","volume":"28","author":"S Siafis","year":"2023","unstructured":"Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023;28:3267\u201377.","journal-title":"Mol Psychiatry"},{"key":"3351_CR146","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41386-021-01132-0","volume":"47","author":"NP Friedman","year":"2022","unstructured":"Friedman NP, Robbins TW. The role of prefrontal cortex in cognitive control and executive function. Neuropsychopharmacology. 2022;47:72\u201389.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63474-1","volume":"14","author":"CM Crisp","year":"2024","unstructured":"Crisp CM, Sahni A, Pang SW, Vanes LD, Szentgyorgyi T, Averbeck B, et al. Deterioration in cognitive control related mPFC function underlying development of treatment resistance in early psychosis. Sci Rep. 2024;14:12985.","journal-title":"Sci Rep"},{"key":"3351_CR148","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41537-023-00384-7","volume":"9","author":"N Gangl","year":"2023","unstructured":"Gangl N, Conring F, Federspiel A, Wiest R, Walther S, Stegmayer K. Resting-state perfusion in motor and fronto-limbic areas is linked to diminished expression of emotion and speech in schizophrenia. Schizophrenia. 2023;9:51.","journal-title":"Schizophrenia"},{"key":"3351_CR149","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/biom12070909","volume":"12","author":"A de Bartolomeis","year":"2022","unstructured":"de Bartolomeis A, Vellucci L, Austin MC, De Simone G, Barone A. Rational and translational implications of D-amino acids for treatment-resistant schizophrenia: from neurobiology to the clinics. Biomolecules. 2022;12:909.","journal-title":"Biomolecules"},{"key":"3351_CR150","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0893-133X(02)00371-8","volume":"27","author":"D Polese","year":"2002","unstructured":"Polese D, de Serpis AA, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology. 2002;27:906\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR151","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/npp.2014.308","volume":"40","author":"KV Wagner","year":"2015","unstructured":"Wagner KV, Hartmann J, Labermaier C, H\u00e4usl AS, Zhao G, Harbich D, et al. Homer1\/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress. Neuropsychopharmacology. 2015;40:1222\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR152","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41386-025-02135-x","volume":"50","author":"H Huang","year":"2025","unstructured":"Huang H, Wang X, Qin X, Xu R, Xiong Y, Chen C, et al. Distinct structural deficits in treatment-resistant schizophrenia and their putative neurotransmitter basis: a source-based morphometry analysis. Neuropsychopharmacology. 2025;50:1807\u201316.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR153","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41386-025-02060-z","volume":"50","author":"I Mantas","year":"2025","unstructured":"Mantas I, Flais I, Branzell N, Ionescu TM, Kim E, Zhang X, et al. A molecular mechanism mediating clozapine-enhanced sensorimotor gating. Neuropsychopharmacology. 2025;50:721\u201330.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR154","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jad.2023.07.003","volume":"339","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2023","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, Navarro D, Torregrosa AB, Viudez-Mart\u00ednez A, Giner S, Manzanares J. Alterations of BDNF, mGluR5, Homer1a, p11 and excitatory\/inhibitory balance in corticolimbic brain regions of suicide decedents. J Affect Disord. 2023;339:366\u201376.","journal-title":"J Affect Disord"},{"key":"3351_CR155","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamapsychiatry.2016.4067","volume":"74","author":"MF Hogan","year":"2017","unstructured":"Hogan MF. Increasing the use of lithium and clozapine in US suicide prevention\u2014reply. JAMA Psychiatry. 2017;74:423\u20134.","journal-title":"JAMA Psychiatry"},{"key":"3351_CR156","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/(SICI)1097-4547(19960701)45:1<13::AID-JNR2>3.0.CO;2-K","volume":"45","author":"R N\u00e4kki","year":"1996","unstructured":"N\u00e4kki R, Sharp FR, Sagar SM, Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J Neurosci Res. 1996;45:13\u201327.","journal-title":"J Neurosci Res"},{"key":"3351_CR157","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41380-020-00878-1","volume":"26","author":"A Mkrtchian","year":"2021","unstructured":"Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, et al. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Mol Psychiatry. 2021;26:3292\u2013301.","journal-title":"Mol Psychiatry"},{"key":"3351_CR158","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1523\/JNEUROSCI.4147-12.2013","volume":"33","author":"DR Thomases","year":"2013","unstructured":"Thomases DR, Cass DK, Tseng KY. Periadolescent exposure to the NMDA receptor antagonist MK-801 impairs the functional maturation of local GABAergic circuits in the adult prefrontal cortex. J Neurosci. 2013;33:26\u201334.","journal-title":"J Neurosci"},{"key":"3351_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03334-2","volume":"15","author":"MT Treadway","year":"2025","unstructured":"Treadway MT, Betters SA, Cooper JA, Li C-X, Zhang X, Michopoulos V. Medial prefrontal glutamate response to acute stress is associated with social subordination in female rhesus macaques. Transl Psychiatry. 2025;15:107.","journal-title":"Transl Psychiatry"},{"key":"3351_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02366-w","volume":"13","author":"T Bonifacino","year":"2023","unstructured":"Bonifacino T, Mingardi J, Facchinetti R, Sala N, Frumento G, Ndoj E, et al. Changes at glutamate tripartite synapses in the prefrontal cortex of a new animal model of resilience\/vulnerability to acute stress. Transl Psychiatry. 2023;13:62.","journal-title":"Transl Psychiatry"},{"key":"3351_CR161","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/j.1471-4159.2009.06088.x","volume":"109","author":"F Fumagalli","year":"2009","unstructured":"Fumagalli F, Pasini M, Frasca A, Drago F, Racagni G, Riva MA. Prenatal stress alters glutamatergic system responsiveness in adult rat prefrontal cortex. J Neurochem. 2009;109:1733\u201344.","journal-title":"J Neurochem"},{"key":"3351_CR162","doi-asserted-by":"publisher","first-page":"108236","DOI":"10.1016\/j.pharmthera.2022.108236","volume":"236","author":"A de Bartolomeis","year":"2022","unstructured":"de Bartolomeis A, Vellucci L, Barone A, Manchia M, De Luca V, Iasevoli F, et al. Clozapine\u2019s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. Pharmacol Ther. 2022;236:108236.","journal-title":"Pharmacol Ther"},{"key":"3351_CR163","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.830757","volume":"16","author":"H Hribkova","year":"2022","unstructured":"Hribkova H, Svoboda O, Bartecku E, Zelinkova J, Horinkova J, Lacinova L, et al. Clozapine reverses dysfunction of glutamatergic neurons derived from clozapine-responsive schizophrenia patients. Front Cell Neurosci. 2022;16:830757.","journal-title":"Front Cell Neurosci"},{"key":"3351_CR164","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1176\/appi.ajp.160.8.1421","volume":"160","author":"C Arango","year":"2003","unstructured":"Arango C, Breier A, McMahon R, Carpenter WT Jr., Buchanan RW. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry. 2003;160:1421\u20137.","journal-title":"Am J Psychiatry"},{"key":"3351_CR165","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0925-4927(03)00108-2","volume":"124","author":"V Molina","year":"2003","unstructured":"Molina V, Reig S, Sarramea F, Sanz J, Francisco Artaloytia J, Luque R, et al. Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia. Psychiatry Res. 2003;124:153\u201361.","journal-title":"Psychiatry Res"},{"key":"3351_CR166","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1038\/npp.2015.90","volume":"40","author":"M Ahmed","year":"2015","unstructured":"Ahmed M, Cannon DM, Scanlon C, Holleran L, Schmidt H, McFarland J, et al. Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment. Neuropsychopharmacology. 2015;40:2409\u201317.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR167","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41537-023-00392-7","volume":"9","author":"TSW Pang","year":"2023","unstructured":"Pang TSW, Chun JSW, Wong TY, Chu ST, Ma CF, Honer WG, et al. A systematic review of neuroimaging studies of clozapine-resistant schizophrenia. Schizophrenia. 2023;9:65.","journal-title":"Schizophrenia"},{"key":"3351_CR168","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s00213-022-06138-0","volume":"239","author":"A Blazer","year":"2022","unstructured":"Blazer A, Chengappa KNR, Foran W, Parr AC, Kahn CE, Luna B, et al. Changes in corticostriatal connectivity and striatal tissue iron associated with efficacy of clozapine for treatment\u2011resistant schizophrenia. Psychopharmacology (Berl). 2022;239:2503\u201314.","journal-title":"Psychopharmacology (Berl)"},{"key":"3351_CR169","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41380-023-02026-x","volume":"28","author":"P Tibrewal","year":"2023","unstructured":"Tibrewal P, Nair PC, Gregory KJ, Langmead CJ, Chan SKW, Bastiampillai T. Does clozapine treat antipsychotic-induced behavioural supersensitivity through glutamate modulation within the striatum? Mol Psychiatry. 2023;28:1839\u201342.","journal-title":"Mol Psychiatry"},{"key":"3351_CR170","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1038\/s41380-021-01235-6","volume":"26","author":"A Kruyer","year":"2021","unstructured":"Kruyer A, Parrilla-Carrero J, Powell C, Brandt L, Gutwinski S, Angelis A, et al. Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity. Mol Psychiatry. 2021;26:6159\u201369.","journal-title":"Mol Psychiatry"},{"key":"3351_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110493","volume":"114","author":"M Matrone","year":"2022","unstructured":"Matrone M, Kotzalidis GD, Romano A, Bozzao A, Cuomo I, Valente F, et al. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022;114:110493.","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"3351_CR172","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/schbul\/sbaa128","volume":"47","author":"A Egerton","year":"2020","unstructured":"Egerton A, Murphy A, Donocik J, Anton A, Barker GJ, Collier T, et al. Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: A multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophr Bull. 2020;47:505\u201316.","journal-title":"Schizophr Bull"},{"key":"3351_CR173","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/schbul\/sbv151","volume":"42","author":"E Mouchlianitis","year":"2016","unstructured":"Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42:744\u201352.","journal-title":"Schizophr Bull"},{"key":"3351_CR174","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41386-019-0589-z","volume":"45","author":"R Tarumi","year":"2020","unstructured":"Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology. 2020;45:632\u201340.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR175","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1017\/S003329172100533X","volume":"53","author":"LC Huang","year":"2023","unstructured":"Huang LC, Lin SH, Tseng HH, Chen KC, Abdullah M, Yang YK. Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study. Psychol Med. 2023;53:3220\u20137.","journal-title":"Psychol Med"},{"key":"3351_CR176","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.schres.2014.10.047","volume":"161","author":"A Alonso-Sol\u00eds","year":"2015","unstructured":"Alonso-Sol\u00eds A, Vives-Gilabert Y, Grasa E, Portella MJ, Rabella M, Sauras RB, et al. Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. Schizophr Res. 2015;161:261\u20138.","journal-title":"Schizophr Res"},{"key":"3351_CR177","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/sj.npp.1300312","volume":"29","author":"AC Lahti","year":"2004","unstructured":"Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, et al. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology. 2004;29:171\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"3351_CR178","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.euroneuro.2022.10.007","volume":"65","author":"V Oliva","year":"2022","unstructured":"Oliva V, De Prisco M. Together is better: Let\u2019s overcome the heterogeneity problem. Eur Neuropsychopharmacol. 2022;65:33\u201334.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3351_CR179","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euroneuro.2023.10.002","volume":"79","author":"M De Prisco","year":"2024","unstructured":"De Prisco M, Vieta E. The never-ending problem: sample size matters. Eur Neuropsychopharmacol. 2024;79:17\u201318.","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03351-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:03:10Z","timestamp":1777017790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03351-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":179,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3351"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03351-z","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, AbbVie, Adamed, Adium, Alcediag, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Casen-Recordati, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Esteve, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Intra-Cellular therapies, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Mitsubishi Tanabe Pharma, Newron, Novartis, Organon, Orion Corporation, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris, outside the submitted work. AdB has received research support from Janssen, Lundbeck, and Otsuka and lecture fees for unrestricted educational meeting from Chiesi, Lundbeck, Roche, Sunovion, Viatris, HIKMA, Tabuk, Recordati, Angelini, Gedeon RIchter and Takeda; he has served on advisory boards for Eli Lilly, Jansen, Lundbeck, Otsuka, Roche, Takeda, Chiesi, Recordati, Angelini, Viatris, Newron, Gedeon Richter. No one of the above competing interest is related directly or indirectly to the work here presented. The other authors have no conflicts of interest to declare with referenced to the present work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}